On November 3, 2026, gynecologic oncology societies affirmed Elahere® (Mirvetuximab soravtansine-gynx 100 mg/20 mL injection) developed by ImmunoGen and AbbVie as the definitive standard of care for folate receptor alpha (FRα)-positive platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Platinum-resistant ovarian cancer has historically carried a dismal prognosis with single-agent chemotherapy yielding objective response rates below 12% and median survival under 12 months. Elahere represents the first antibody-drug conjugate (ADC) to demonstrate statistically significant overall survival superiority over chemotherapy in this population.

Through Critical Kare Pharma, certified genuine packs of Elahere Mirvetuximab Soravtansine 100mg Injection are delivered to oncology clinics worldwide under strict 2°C–8°C cold chain.

The MIRASOL Phase 3 Trial Benchmarks

The confirmatory global Phase 3 MIRASOL trial enrolled 453 patients with high FRα-expressing platinum-resistant ovarian cancer who had received one to three prior systemic therapies:

• Overall Survival Advantage: Elahere achieved a 33% reduction in risk of death compared to investigator's choice chemotherapy (paclitaxel, pegylated liposomal doxorubicin, or topotecan), extending median overall survival to 16.5 months versus 12.8 months (HR 0.67, p = 0.0046).
• Progression-Free Survival: Reduced risk of disease progression or death by 35% (median PFS 5.6 vs 4.0 months; HR 0.65, p < 0.0001).
• Objective Response Rate (ORR): 42.3% with Elahere (including 12 complete responses) compared to only 15.9% with chemotherapy.

ADC Architecture: FRα Targeting with DM4 Maytansinoid Payload

• Antibody: Chimeric IgG1 monoclonal antibody targeting folate receptor alpha, which is overexpressed on >80% of high-grade serous ovarian carcinomas while minimally expressed on healthy tissues.
• Cleavable Disulfide Linker: Stable in circulation but cleaved intracellularly by glutathione upon endocytosis.
• DM4 Payload: Potent tubulin-disrupting maytansinoid that arrests mitosis in G2/M phase, with bystander cell killing capability against adjacent heterogeneous tumor cells.

Ophthalmic Monitoring Protocol

DM4 can cause transient corneal epithelial microcysts. Comprehensive preventive protocols include mandatory baseline ophthalmic exams, lubricating eye drops daily, and vasoconstrictor/corticosteroid eye drops during infusion.

Global Sourcing & Dispatch

Supplied under GDP cold-chain compliance (2°C–8°C) with continuous electronic temperature data loggers via Critical Kare Pharma.